&Partners’s Teva Pharmaceuticals TEVA Stock Holding History

&Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$997K	Buy	29,413 +1,091	+4%	+$36.3K	﹤0.01%	1416
2026 Q1	$853K	Buy	28,322 +5,607	+25%	+$180K	﹤0.01%	1386
2025 Q4	$709K	Sell	22,715 -32,856	-59%	-$809K	﹤0.01%	1423
2025 Q3	$1.12M	Buy	55,571 +2,177	+4%	+$38.2K	0.01%	1031
2025 Q2	$895K	Buy	53,394 +23,280	+77%	+$376K	0.01%	1038
2025 Q1	$452K	Sell	30,114 -412	-1%	-$7.36K	﹤0.01%	1186
2024 Q4	$649K	Sell	30,526 -2,823	-8%	-$51.4K	0.01%	952
2024 Q3	$602K	Buy	+33,349	New	+$584K	0.01%	776

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

&Partners's TEVA Position: Q2 2026 in Review

&Partners increased its Teva Pharmaceuticals (TEVA) stake by 3.9% in Q2 2026, buying an estimated $36.3K and bringing the position to 29,413 shares worth $997K. The position accounts for ﹤0.01% of the portfolio, ranked #1416.

&Partners first reported a position in TEVA in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.12M in Q3 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

&Partners held 29,413 shares of Teva Pharmaceuticals worth $997K as of Q2 2026.
&Partners bought 1,091 Teva Pharmaceuticals shares in Q2 2026, an estimated $36.3K.
Teva Pharmaceuticals made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #1416 holding.
&Partners first reported a position in Teva Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
&Partners's Teva Pharmaceuticals position peaked at $1.12M in Q3 2025.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.